Quick Answer
Syndax Pharmaceuticals Inc reported Operating Income of -$273.08 million for fiscal year 2025.
Syndax Pharmaceuticals Inc Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$273.08M | +19.6% |
| 2024 | -$339.67M | -47.7% |
| 2023 | -$229.95M | -51.5% |
| 2022 | -$151.76M | -678.8% |
| 2021 | $26.22M | +136.7% |
| 2020 | -$71.42M | -24.1% |
| 2019 | -$57.54M | +24.2% |
| 2018 | -$75.88M | -22.5% |
| 2017 | -$61.95M | -41.6% |
| 2016 | -$43.77M | -113.4% |
| 2015 | -$20.51M | +3.8% |
| 2014 | -$21.33M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$57.43M | +35.9% | +17.2% |
| June 30, 2025 | -$69.35M | +6.6% | +17.2% |
| March 31, 2025 | -$83.76M | -5.3% | +6.5% |
| September 30, 2024 | -$89.58M | -59.0% | -20.7% |
| June 30, 2024 | -$74.22M | -49.4% | +6.7% |
| March 31, 2024 | -$79.51M | -72.8% | -41.1% |
| September 30, 2023 | -$56.35M | -60.4% | -13.4% |
| June 30, 2023 | -$49.68M | -31.7% | -8.0% |
- Syndax Pharmaceuticals Inc showed an increase of +19.6% in Operating Income compared to the prior fiscal year.
- Over the 2014–2025 period, Syndax Pharmaceuticals Inc’s operating income has declined by 1180.2% (from -$21.33 million to -$273.08 million).
- The most recent figure is from Syndax Pharmaceuticals Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: